Cipher Pharmaceuticals Inc

Type: Company
Name: Cipher Pharmaceuticals Inc
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Revera Board Appoints Thomas G. Wellner as President and Chief Executive Officer

/CNW/ - Revera Inc. is pleased to announce that its Board of Directors has appointed Thomas G. Wellner as President and Chief Executive Officer, effective immediately.Mr. Wellner was most recently co-CEO of LifeLabs, and was previously President and CEO ... [Published Canada NewsWire - Apr 14 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

Update on Isotretinoin Usage for Severe Acne

In an effort to wade through concerning and often confusing claims relating to the use of isotretinoin for patient with severe acne, American Academy of Dermatology expert William D. James, MD, FAAD, has reviewed the most recent literature to offer guidance ... [Published MedEsthetics Magazine - Apr 03 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

Cipher names Thomas Wellner to board

Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND) has appointed Thomas Wellner to the board. Most recently, Mr. Wellner was co-CEO of LifeLabs, Canada’s largest laboratory services company, where he was responsible for leading the integration of CML HealthCare ... [Published BioPortfolio - Mar 25 2014]
First reported Mar 20 2014 - Updated Mar 20 2014 - 1 reports

Cipher Pharmaceuticals announces departure of president and CEO

Cipher Pharmaceuticals Inc. has announced that Larry Andrews will be stepping down from his position as president and CEO. To ensure a smooth transition of responsibilities, Mr Andrews will remain with the Company for a period of time while the Board ... [Published Individual.com - Mar 20 2014]
First reported Mar 14 2014 - Updated Mar 14 2014 - 2 reports

Larry Andrews steps down as Cipher Pharma head

Larry Andrews will be stepping down from his position as president and CEO of Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND). To ensure a smooth transition of responsibilities, Mr. Andrews will remain with the company for a period of time while the board ... [Published BioPortfolio - Mar 14 2014]
First reported Mar 14 2014 - Updated Mar 14 2014 - 1 reports

CIPHER PHARMACEUTICALS : announces management change

Toronto Stock Exchange Symbol: DNDMISSISSAUGA, ON , March 14, 2014 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that LarryAndrews will be stepping down from his position as President and ChiefExecutive Officer. ... [Published 4 Traders - Mar 14 2014]
First reported Feb 26 2014 - Updated Feb 26 2014 - 1 reports

Cipher Pharmaceuticals earns $25-million in 2013

Cipher Pharmaceuticals Inc. today released its financial and operational results for the three and 12 months ended Dec. 31, 2013.Fiscal 2013 HighlightsTotal revenue of $27.0 million, compared with $8.5 million in 2012; Q4 2013 revenue was a quarterly ... [Published Stockwatch - Feb 26 2014]
First reported Feb 05 2014 - Updated Feb 06 2014 - 1 reports

Cipher Pharmaceuticals names McDole chairman

Cipher Pharmaceuticals Inc. has appointed Gerald (Gerry) McDole as chairman of the board of directors of the company effective immediately. Mr. McDole has been a member of Cipher's board since 2004. Mr. McDole replaces William Garriock, who, as previously ... [Published Stockwatch - Feb 05 2014]
First reported Jan 21 2014 - Updated Jan 21 2014 - 1 reports

Cipher receives Absorica sales milestone payment

Cipher Pharmaceuticals Inc.'s marketing partner for Absorica has reached a cumulative sales milestone in accordance with the parties' commercial agreement, triggering a one-time $5.0-million (U.S.) (net) payment to Cipher. This revenue will be included ... [Published Stockwatch - Jan 21 2014]
First reported Jan 09 2014 - Updated Jan 09 2014 - 1 reports

Globe says Gluskin, others have good earnings momentum

Close 2014-01-08 C$ 26.30 Recent Sedar DocumentsView Original Document Also In the News (C-AVO) Avigilon CorpAlso In the News (C-CAM) Canam Group IncAlso In the News (C-DND) Cipher Pharmaceuticals IncAlso In the News (C-SUM) Solium Capital IncAlso In ... [Published Stockwatch - Jan 09 2014]

Quotes

...competitive private and public business environments, will be a strong asset to Revera," said Neil Cunningham, Chair of Revera's Board of Directors. "He has a track record of success running large, complex businesses and brings a passion for innovation, people and customers. We are pleased to welcome him as CEO."
...of the Board and all the employees, I want to thank Larry for many years of dedicated service to Cipher," said Gerry McDole, Chair of Cipher. "Larry has led Cipher for its entire life as a public company and has been instrumental in the company's regulatory and commercial success. We wish him all the best in his future endeavors and look forward to his continued contributions in a consulting capacity."
"With strong financial performance, a growing cash balance, and a"
...we achieved in the fourth quarter, helped drive significant revenue and earnings growth in 2013," said Larry Andrews, President and CEO of Cipher. "Our other products also made solid contributions in 2013 and we built a commercial footprint in Canada to launch our first product - Epuris - which has been well received by the Canadian dermatology community. We are focused on using our growing cash balance to acquire new products in specialist-driven markets, such as dermatology."

More Content

All (14) | News (14) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Revera Board Appoints Thomas G. Wellner as Pres... [Published Canada NewsWire - Apr 14 2014]
Update on Isotretinoin Usage for Severe Acne [Published MedEsthetics Magazine - Apr 03 2014]
Cipher names Thomas Wellner to board [Published BioPortfolio - Mar 25 2014]
Cipher Pharmaceuticals announces departure of p... [Published Individual.com - Mar 20 2014]
Larry Andrews steps down as Cipher Pharma head [Published BioPortfolio - Mar 14 2014]
Cipher Pharmaceuticals Inc announces Larry Andr... [Published Reuters UK - Mar 14 2014]
CIPHER PHARMACEUTICALS : announces management c... [Published 4 Traders - Mar 14 2014]
Cipher Pharmaceuticals earns $25-million in 2013 [Published Stockwatch - Feb 26 2014]
Cipher Pharmaceuticals names McDole chairman [Published Stockwatch - Feb 05 2014]
Cipher receives Absorica sales milestone payment [Published Stockwatch - Jan 21 2014]
Globe says Gluskin, others have good earnings m... [Published Stockwatch - Jan 09 2014]
Ranbaxy gets Paragraph IV Certification Notice ... [Published PharmaBiz - Sep 20 2013]
North American Drug Delivery Technologies Marke... [Published PRWeb - Jul 23 2013]
Ranbaxy gets US approval to launch Absorica [Published Topnews.in - May 30 2012]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.